Cystic Fibrosis Clinical Trial
Official title:
Study of Cardiac MRI to Assess Pulmonary Perfusion and Pulmonary Hemodynamics in Patients With Cystic Fibrosis Study (Pilot 3)
The purpose of this research is to learn more about the heart and blood vessels in the lungs
of people with cystic fibrosis (CF). This study will include approximately 36 children and
adults with CF and 12 children and adults without CF. The study will involve one magnetic
resonance imaging (MRI) . The research also includes blood samples to look at inflammation
and lung tests called spirometry and Lung Clearance Index (LCI) determined by Multiple Breath
Washout test.
For the CF subjects, enrollment will be timed to coincide with routine scheduled computerized
tomography (CT) or the CF subject may choose to have a CT for research purposes. The MRI will
be compared to CT images of the lungs. The goal is to develop better imaging that does not
use radiation.
Cystic Fibrosis (CF), the most common inherited disease in Caucasians, is characterized by
chronic pulmonary inflammation and progressive loss of gas exchange units that eventually
results in respiratory failure. There is strong evidence that in CF abnormally low vascular
perfusion carries a high risk of death independent from the presence of pulmonary
hypertension. However, the evolution of pulmonary vascular disease in CF and how it might
contribute to the rate of decline in lung function is not known. Knowledge remains limited to
the results of old observational studies which concluded that the major causes of pulmonary
vascular remodeling and hypertension in CF are hypoxic respiratory failure and destruction of
lung tissue. Recent data obtained by state-of-the-art Magnetic Resonance Imaging (MRI) of the
pulmonary circulation, challenges the existing paradigm. Studies demonstrate that in the
absence of hypoxia, significant changes in pulmonary perfusion and in surrogate measures of
vascular resistance as well as in collateral blood flow begin early in the course of CF. The
newly developed therapeutics in the last decade which altered dramatically the course of
patients suffering from pulmonary vascular disease provide opportunities to understand the
role of pulmonary vasculature in CF lung disease.
This pilot study (Pilot 3) will assess the relationships between pulmonary perfusion, serum
markers of pulmonary inflammation and vascular remodeling, and hemodynamic measures
consistent with pulmonary hypertension. This study will establish MRI as a readily obtainable
modality to be used in the CF population to obtain measurements of pulmonary perfusion;
pulmonary arterial hemodynamic, dimension, and flow measures; and ventricular mass and
function measures.
The primary goal of this study is to improve the understanding of pulmonary vascular disease
in CF by examining pulmonary perfusion abnormalities and their association with markers of
pulmonary inflammation and pulmonary vascular remodeling, the severity of obstructive airways
disease, and pulmonary hemodynamic abnormalities in CF.
This study will include a single MRI of the pulmonary circulation on about 36 pediatric and
adult patients with CF and about 12 non-CF controls. UTE (Ultrashort Echo Time) MRI will be
performed without contrast. CF patients who are scheduled for clinical chest CT will be
enrolled and the scheduling of the MRI will be coordinated with the clinical CT. CF subjects
may also choose to enroll independent of clinical CT and choose to have a CT for research
purposes only. Other study procedures include blood specimen for serum biomarkers and lung
tests called spirometry and Lung Clearance Index (LCI) determined by Multiple Breath Washout
test. Blood specimens will be analyzed for a panel of inflammatory markers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |